Spots Global Cancer Trial Database for cadonilimab
Every month we try and update this database with for cadonilimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer | NCT06154538 | Locally Advance... | Cadonilimab FOLFOX regimen | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer | NCT06155422 | Recurrent or Me... | Cadonilimab | 18 Years - 90 Years | Tongji Hospital | |
| To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. | NCT05948449 | Gastric Cancer | S-1, Oxaliplati... | 18 Years - 75 Years | Sichuan University | |
| Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer | NCT06154538 | Locally Advance... | Cadonilimab FOLFOX regimen | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) | NCT06341660 | Non-small Cell ... | cadonilimab | 18 Years - 75 Years | Guangzhou Institute of Respiratory Disease | |
| Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors | NCT05915481 | Advanced Solid ... Stereotactic Bo... Immune Checkpoi... Safety Efficacy | Cadonilimab Stereotactic bo... | 18 Years - 75 Years | Peking University Third Hospital | |
| Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma | NCT05656144 | Soft Tissue Sar... | Cadonilimab | 18 Years - 70 Years | Peking University Cancer Hospital & Institute | |
| A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer | NCT06331650 | Non-small Cell ... | cadonilimab | 18 Years - 75 Years | Guangzhou Institute of Respiratory Disease | |
| Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases | NCT05812534 | Non Small Cell ... Brain Metastase... | Cadonilimab | 18 Years - | Second Affiliated Hospital of Nanchang University | |
| Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer | NCT05426005 | Colorectal Canc... Mismatch Repair... Microsatellite ... | Cadonilimab | 18 Years - | Sun Yat-sen University | |
| Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy | NCT05990231 | Esophageal Squa... | Cadonilimab com... | 18 Years - 80 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases | NCT06265350 | Hepatocellular ... Liver Cancer St... Pulmonary Metas... Cadonilimab Bevacizumab Cryoablation | Cadonilimab Bevacizumab Cryoablation | 18 Years - 75 Years | Sun Yat-sen University | |
| Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer | NCT06289751 | Cervical Cancer Neoadjuvant Che... Radical Hystere... Fertility Prese... | Cadonilimab Paclitaxel-albu... Cisplatin Extrafascial hy... | 18 Years - 70 Years | Tongji Hospital | |
| Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer | NCT06009848 | Bladder Cancer | Cadonilimab | 18 Years - | Tianjin Medical University Second Hospital | |
| Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma | NCT06023875 | Head and Neck S... Locally Advance... | Cadonilimab Docetaxel Cisplatin | 18 Years - 70 Years | Sun Yat-sen University | |
| Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer | NCT06218810 | Metastatic Colo... Microsatellite ... RAS Mutation Cadonilimab | Cadonilimab + b... | 18 Years - 75 Years | Fudan University | |
| Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma | NCT05656144 | Soft Tissue Sar... | Cadonilimab | 18 Years - 70 Years | Peking University Cancer Hospital & Institute | |
| Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab | NCT05737368 | Recurrent Gliob... | fractionated ra... cadonilimab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer | NCT05426005 | Colorectal Canc... Mismatch Repair... Microsatellite ... | Cadonilimab | 18 Years - | Sun Yat-sen University | |
| Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer | NCT06367088 | Triple-negative... Cadonilimab | Cadonilimab | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer | NCT05839470 | Colorectal Canc... | cadonilimab irinotecan Oxaliplatin leucovorin or l... 5-FU | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases | NCT06265350 | Hepatocellular ... Liver Cancer St... Pulmonary Metas... Cadonilimab Bevacizumab Cryoablation | Cadonilimab Bevacizumab Cryoablation | 18 Years - 75 Years | Sun Yat-sen University | |
| Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer | NCT06202313 | Triple Negative... | Cadonilimab Eribulin | 18 Years - 75 Years | Shengjing Hospital | |
| A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer | NCT06331650 | Non-small Cell ... | cadonilimab | 18 Years - 75 Years | Guangzhou Institute of Respiratory Disease | |
| Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma | NCT06023875 | Head and Neck S... Locally Advance... | Cadonilimab Docetaxel Cisplatin | 18 Years - 70 Years | Sun Yat-sen University | |
| Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI | NCT06277674 | Non-small Cell ... | Cadonilimab plu... | 65 Years - | Guangzhou University of Traditional Chinese Medicine | |
| Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT05816499 | NSCLC Stage IV NSCLC Stage III... NSCLC Stage III... | Cadonilimab Anlotinib Docetaxel | 18 Years - | Shanghai Chest Hospital | |
| Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma | NCT06187961 | Hepatocellular ... | HAIC Lenvatinib plus... | 18 Years - 75 Years | Tongji Hospital | |
| Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure | NCT06327698 | Melanoma | Cadonilimab anlotinib | 18 Years - 75 Years | Hunan Cancer Hospital | |
| Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors | NCT05915481 | Advanced Solid ... Stereotactic Bo... Immune Checkpoi... Safety Efficacy | Cadonilimab Stereotactic bo... | 18 Years - 75 Years | Peking University Third Hospital | |
| Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance | NCT06118645 | Gastric Adenoca... | cadonilimab com... | 18 Years - 75 Years | China Medical University, China | |
| Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer | NCT06202313 | Triple Negative... | Cadonilimab Eribulin | 18 Years - 75 Years | Shengjing Hospital | |
| Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer | NCT06140589 | Cervical Cancer | Cadonilimab | 18 Years - 80 Years | Fujian Cancer Hospital | |
| Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial | NCT06310473 | Gastric Cancer Esophagogastric... | Cadonilimab Oxaliplatin Capecitabine | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer | NCT06140589 | Cervical Cancer | Cadonilimab | 18 Years - 80 Years | Fujian Cancer Hospital | |
| Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors | NCT05915481 | Advanced Solid ... Stereotactic Bo... Immune Checkpoi... Safety Efficacy | Cadonilimab Stereotactic bo... | 18 Years - 75 Years | Peking University Third Hospital | |
| A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma | NCT06356688 | Locally Advance... Neoadjuvant The... | paclitaxel poly... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance | NCT06118645 | Gastric Adenoca... | cadonilimab com... | 18 Years - 75 Years | China Medical University, China | |
| TIPS Plus Cadonilimab in Advanced HCC With Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study | NCT05882370 | Hepatocellular ... | Cadonilimab transjugular in... | 18 Years - 75 Years | Sun Yat-sen University | |
| To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. | NCT05948449 | Gastric Cancer | S-1, Oxaliplati... | 18 Years - 75 Years | Sichuan University | |
| AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) | NCT05578430 | Resectable Hepa... | Cadonilimab TACE Surgery | 18 Years - 75 Years | Sun Yat-sen University | |
| Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer | NCT05815290 | dMMR Colorectal... | Cadonilimab | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | NCT06335927 | Intrahepatic Ch... | HAIC-GEMOX+Cado... | 18 Years - 75 Years | Fudan University | |
| Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma | NCT05656144 | Soft Tissue Sar... | Cadonilimab | 18 Years - 70 Years | Peking University Cancer Hospital & Institute | |
| Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer | NCT05839470 | Colorectal Canc... | cadonilimab irinotecan Oxaliplatin leucovorin or l... 5-FU | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma | NCT06416930 | Pleural Mesothe... | Cadonilimab Com... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer | NCT05815303 | Rectal Cancer MSS | Cadonilimab Oxaliplatin Capecitabine | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer | NCT06154538 | Locally Advance... | Cadonilimab FOLFOX regimen | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative | NCT06001151 | Carcinoma, Non-... | Cadonilimab Pemetrexed Carboplatin | 18 Years - 75 Years | Tongji Hospital | |
| Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer | NCT05815290 | dMMR Colorectal... | Cadonilimab | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer | NCT05815303 | Rectal Cancer MSS | Cadonilimab Oxaliplatin Capecitabine | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT05898256 | Nasopharyngeal ... Immune Checkpoi... | Cadonilimab Gemcitabine Cisplatin | 18 Years - 65 Years | Guangxi Medical University | |
| Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer | NCT05974059 | Locally Advance... | Oxaliplatin Capecitabine Cadonilimab | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI | NCT06277674 | Non-small Cell ... | Cadonilimab plu... | 65 Years - | Guangzhou University of Traditional Chinese Medicine | |
| A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | NCT06341335 | Gastric and Gas... | cadonilimab pulocimab paclitaxel placebo | 18 Years - 75 Years | Akeso | |
| Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006) | NCT06143748 | Esophagus Cance... | Cadonilimab Paclitaxel and ... intensity-modul... | 18 Years - 75 Years | Sun Yat-sen University | |
| TIPS Plus Cadonilimab in Advanced HCC With Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study | NCT05882370 | Hepatocellular ... | Cadonilimab transjugular in... | 18 Years - 75 Years | Sun Yat-sen University | |
| Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases | NCT06265350 | Hepatocellular ... Liver Cancer St... Pulmonary Metas... Cadonilimab Bevacizumab Cryoablation | Cadonilimab Bevacizumab Cryoablation | 18 Years - 75 Years | Sun Yat-sen University | |
| AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer | NCT06196697 | Gastric Adenoca... Gastroesophagea... | Cadonilimab Ivonescimab XELOX SOX | 18 Years - 75 Years | Harbin Medical University | |
| Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer | NCT06289751 | Cervical Cancer Neoadjuvant Che... Radical Hystere... Fertility Prese... | Cadonilimab Paclitaxel-albu... Cisplatin Extrafascial hy... | 18 Years - 70 Years | Tongji Hospital | |
| Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative | NCT06001151 | Carcinoma, Non-... | Cadonilimab Pemetrexed Carboplatin | 18 Years - 75 Years | Tongji Hospital | |
| Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma | NCT05790200 | Nasopharyngeal ... | Cadonilimab | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure | NCT06327698 | Melanoma | Cadonilimab anlotinib | 18 Years - 75 Years | Hunan Cancer Hospital | |
| Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT05816499 | NSCLC Stage IV NSCLC Stage III... NSCLC Stage III... | Cadonilimab Anlotinib Docetaxel | 18 Years - | Shanghai Chest Hospital | |
| Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors | NCT05824494 | Uterine Cervica... Cancer of Cervi... Cervical Cancer Cervical Neopla... Uterine Cervica... Cancer of the U... | Cadonilimab Nab paclitaxel | 18 Years - 75 Years | Women's Hospital School Of Medicine Zhejiang University | |
| Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | NCT06040177 | Hepatocellular ... Portal Vein Tum... Immune Checkpoi... | Cadonilimab Stereotactic ra... Renvatinib | 18 Years - 70 Years | First Affiliated Hospital of Guangxi Medical University | |
| SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC | NCT05732662 | Recurrent or Me... | SBRT Cadonilimab | 18 Years - | The First People's Hospital of Changzhou |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
